...
首页> 外文期刊>Bone marrow transplantation >Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia.
【24h】

Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia.

机译:特发性再生障碍性贫血儿童的无关脐血移植。

获取原文
获取原文并翻译 | 示例

摘要

Early results of unrelated cord blood transplantation (UCBT) for severe aplastic anemia (SAA) were poor with a high rate of engraftment failure. This was attributed to the combination of lower graft cell dose and intact host immune system. We performed UCBT in nine children (median age 9 years) with refractory SAA using increasingly immunosuppressive preparative regimens. The time from diagnosis to UCBT was 3.4-20 months (median age 7.2 years), with all children having failed at least one course of immunosuppression. Donor/recipient HLA matching was six of six (n=1), five of six (n=2) and four of six (n=6). The median nucleated cell dose infused was 5.7 x 10(7) cells/kg (range 3.5-20 x 10(7) cells/kg). Six patients were engrafted after the first UCBT. Two of the three patients without hematopoietic reconstitution were engrafted after a second UCBT. All children receiving >or=120 mg/kg of CY in the preparative regimen were engrafted. The median time to myeloid engraftment was 25 (17-59 days) days. AcuteGVHD developed in two, and chronic GVHD in five patients. Five patients developed EBV viremia post transplant (lymphoproliferative disorder in three patients). At a median follow-up of 34 months, seven patients are alive and transfusion-independent. UCBT is a feasible treatment strategy for children with refractory SAA lacking a well-matched adult donor.
机译:严重再生障碍性贫血(SAA)的无关脐血移植(UCBT)的早期结果较差,且移植失败率很高。这归因于较低的移植细胞剂量和完整的宿主免疫系统的结合。我们使用越来越多的免疫抑制性制备方案,对9名难治性SAA儿童(中位年龄9岁)进行了UCBT。从诊断到UCBT的时间为3.4-20个月(中位年龄7.2岁),所有儿童均至少经历了一个免疫抑制疗程失败。供体/接受者HLA匹配为六个中的六个(n = 1),六个中的五个(n = 2)和六个中的四个(n = 6)。注入的中位数有核细胞剂量为5.7 x 10(7)细胞/ kg(范围3.5-20 x 10(7)细胞/ kg)。首次UCBT后有6例患者被植入。在第二次UCBT后,将三例无造血重建的患者中的两例移植。将所有在准备方案中接受≥120mg / kg CY的儿童植入。骨髓植入的中位时间为25(17-59天)天。 AcuteGVHD有2例发生,慢性GVHD有5例。五位患者在移植后出现EBV病毒血症(三位患者的淋巴增生性疾病)。在34个月的中位随访中,有7名患者还活着并且与输血无关。对于缺乏匹配的成人供体的难治性SAA儿童,UCBT是一种可行的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号